Anemia and iron deficit anemia in children under five years of age and their relation with iron consumption in alimentation. Turbo, Antioquia, Colombia

ABSTRACT: To determine the frequency of anemia and iron deficit anemia in relation to the iron content in the alimentation of children from 6 months to five years in Turbo. Methodology and materials: transversal descriptive study of 113 children attending the growth, development and vaccination program clinic, from September 2001 to June 2002 in the Francisco Valderrama Hospital, Turbo. Laboratory tests were Hb ferritin, direct coprological and hidden blood in feces. Dietary iron was studied by a semi structural survey. Results and discussion: Hb average 11.3 g/dL (SD 1.4) Anemia: 48.7%. More affected were minors under one year. Ferritin average: 47.1 Ng/L low ferritin present in 50.4% of children and from those 23.6% show exhaustion of iron deposits. From 55 children with anemia 23.6% show iron deficit anemia. Average iron consumption 7.1 mg/day. Average heminic iron 3.9 mg /day. Average exclusive maternal lactation: 3 months. Lactation alternates with pasteurized cow milk. From every 10 children under 1 year of age 6 show iron deficit anemia. Conclusions: anemia, low ferritin and low iron consumption point to a serious public health problem. A clear policy articulated with popular culture is badly needed to prevent this problem and its consequences for the growth, development and cognitive capacities of the children.RESUMEN: Determinar la frecuencia de anemia y de anemia por deficiencia de hierro y su relación con el contenido de hierro en la alimentación en niños de 6 meses a 5 años. Materiales y métodos: Estudio descriptivo de corte transversal en el que se estudiaron 113 niños que asistieron a la consulta de crecimiento y desarrollo y al programa de vacunación de la ESE Hospital Francisco Valderrama de Turbo entre el mes de septiembre de 2001 y el mes de junio de 2002. Las pruebas de laboratorio empleadas fueron Hb, ferritina, coprológico directo y sangre oculta en heces. El hierro dietario se estudió con una encuesta semiestructurada. Resultados y discusión: Promedio de Hb 11,3 g/dl (DE 1,4); presentan anemia 48,7%, los más afectados fueron los menores de un año. Promedio de ferritina 47,1 μg/L (DE 58,7), mediana 23,3 μg/L; 50,4% presentan ferritina baja y de estos, 23,9% presentan agotamiento en los depósitos de hierro. De los 55 niños con anemia 23,6% presentan anemia con deficiencia de hierro. Promedio en el consumo de hierro 7,1 mg/día (DE 3,96); promedio de hierro hemínico de 3,9 mg/día. Promedio de lactancia materna exclusiva: 3 meses. La lactancia se alterna con leche de vaca pasteurizada. De cada 10 menores de un año, 6 tienen anemia con déficit de hierro. Conclusiones: La anemia, la ferritina baja y el bajo consumo de hierro en los niños estudiados perfilan un grave problema de salud pública. Se requiere una política clara y articulada a la cultura de la población para prevenir este problema y sus secuelas en el crecimiento, el desarrollo y en la capacidad cognitiva de los niños

Anemia y anemia por déficit de hierro en niños menores de cinco años y su relación con el consumo de hierro en la alimentación. Turbo, Antioquia, Colombia

Objective: to determine the frequency of anemia and iron deficit anemia in relation to the iron content in the alimentation of children from 6 months to five years in Turbo. Methodology and materials: transversal descriptive study of 113 children attending the growth, development and vaccination program clinic, from September 2001 to June 2002 in the Francisco Valderrama Hospital, Turbo. Laboratory tests were Hb ferritin, direct coprological and hidden blood in feces. Dietary iron was studied by a semi structural survey. Results and discussion: Hb average 11.3 g/dL (SD 1.4) Anemia: 48.7%. More affected were minors under one year. Ferritin average: 47.1 Ng/L low ferritin present in 50.4% of children and from those 23.6% show exhaustion of iron deposits. From 55 children with anemia 23.6% show iron deficit anemia. Average iron consumption 7.1 mg/day. Average heminic iron 3.9 mg /day. Average exclusive maternal lactation: 3 months. Lactation alternates with pasteurized cow milk. From every 10 children under 1 year of age 6 show iron deficit anemia. Conclusions: anemia, low ferritin and low iron consumption point to a serious public health problem. A clear policy articulated with popular culture is badly needed to prevent this problem and its consequences for the growth, development and cognitive capacities of the children.Objetivo: Determinar la frecuencia de anemia y de anemia por deficiencia de hierro y su relación con el contenido de hierro en la alimentación en niños de 6 meses a 5 años. Materiales y métodos: Estudio descriptivo de corte transversal en el que se estudiaron 113 niños que asistieron a la consulta de crecimiento y desarrollo y al programa de vacunación de la ESE Hospital Francisco Valderrama de Turbo entre el mes de septiembre de 2001 y el mes de junio de 2002. Las pruebas de laboratorio empleadas fueron Hb, ferritina, coprológico directo y sangre oculta en heces. El hierro dietario se estudió con una encuesta semiestructurada. Resultados y discusión: Promedio de Hb 11,3 g/dl (DE 1,4); presentan anemia 48,7%, los más afectados fueron los menores de un año. Promedio de ferritina 47,1 µg/L (DE 58,7), mediana 23,3 µg/L.; 50,4% presentan ferritina baja y de estos, 23,9% presentan agotamiento en los depósitos de hierro. De los 55 niños con anemia 23,6% presentan anemia con deficiencia de hierro. Promedio en el consumo de hierro 7,1 mg/día (DE 3,96); promedio de hierro hemínico de 3,9 mg/día. Promedio de lactancia materna exclusiva: 3 meses. La lactancia se alterna con leche de vaca pasteurizada. De cada 10 menores de un año, 6 tienen anemia con déficit de hierro. Conclusiones: La anemia, la ferritina baja y el bajo consumo de hierro en los niños estudiados perfilan un grave problema de salud pública. Se requiere una política clara y articulada a la cultura de la población para prevenir este problema y sus secuelas en el crecimiento, el desarrollo y en la capacidad cognitiva de los niños

Anemia y anemia por déficit de hierro en niños menores de cinco años y su relación con el consumo de hierro en la alimentación. Turbo, Antioquia, Colombia Anemia and iron deficit anemia in children under five years of age and their relation with iron consumption in alimentation, Turbo, Antioquia, Colombia

Objetivo: Determinar la frecuencia de anemia y de anemia por deficiencia de hierro y su relación con el contenido de hierro en la alimentación en niños de 6 meses a 5 años. Materiales y métodos: Estudio descriptivo de corte transversal en el que se estudiaron 113 niños que asistieron a la consulta de crecimiento y desarrollo y al programa de vacunación de la ESE Hospital Francisco Valderrama de Turbo entre el mes de septiembre de 2001 y el mes de junio de 2002. Las pruebas de laboratorio empleadas fueron Hb, ferritina, coprológico directo y sangre oculta en heces. El hierro dietario se estudió con una encuesta semiestructurada. Resultados y discusión: Promedio de Hb 11,3 g/dl (DE 1,4); presentan anemia 48,7%, los más afectados fueron los menores de un año. Promedio de ferritina 47,1 µg/L (DE 58,7), mediana 23,3 µg/L.; 50,4% presentan ferritina baja y de estos, 23,9% presentan agotamiento en los depósitos de hierro. De los 55 niños con anemia 23,6% presentan anemia con deficiencia de hierro. Promedio en el consumo de hierro 7,1 mg/día (DE 3,96); promedio de hierro hemínico de 3,9 mg/día. Promedio de lactancia materna exclusiva: 3 meses. La lactancia se alterna con leche de vaca pasteurizada. De cada 10 menores de un año, 6 tienen anemia con déficit de hierro. Conclusiones: La anemia, la ferritina baja y el bajo consumo de hierro en los niños estudiados perfilan un grave problema de salud pública. Se requiere una política clara y articulada a la cultura de la población para prevenir este problema y sus secuelas en el crecimiento, el desarrollo y en la capacidad cognitiva de los niños.Objective: to determine the frequency of anemia and iron deficit anemia in relation to the iron content in the alimentation of children from 6 months to five years in Turbo. Methodology and materials: transversal descriptive study of 113 children attending the growth, development and vaccination program clinic, from September 2001 to June 2002 in the Francisco Valderrama Hospital, Turbo. Laboratory tests were Hb ferritin, direct coprological and hidden blood in feces. Dietary iron was studied by a semi structural survey. Results and discussion: Hb average 11.3 g/dL (SD 1.4) Anemia: 48.7%. More affected were minors under one year. Ferritin average: 47.1 Ng/L low ferritin present in 50.4% of children and from those 23.6% show exhaustion of iron deposits. From 55 children with anemia 23.6% show iron deficit anemia. Average iron consumption 7.1 mg/day. Average heminic iron 3.9 mg /day. Average exclusive maternal lactation: 3 months. Lactation alternates with pasteurized cow milk. From every 10 children under 1 year of age 6 show iron deficit anemia. Conclusions: anemia, low ferritin and low iron consumption point to a serious public health problem. A clear policy articulated with popular culture is badly needed to prevent this problem and its consequences for the growth, development and cognitive capacities of the childre

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk

Health-status outcomes with invasive or conservative care in coronary disease

BACKGROUND In the ISCHEMIA trial, an invasive strategy with angiographic assessment and revascularization did not reduce clinical events among patients with stable ischemic heart disease and moderate or severe ischemia. A secondary objective of the trial was to assess angina-related health status among these patients. METHODS We assessed angina-related symptoms, function, and quality of life with the Seattle Angina Questionnaire (SAQ) at randomization, at months 1.5, 3, and 6, and every 6 months thereafter in participants who had been randomly assigned to an invasive treatment strategy (2295 participants) or a conservative strategy (2322). Mixed-effects cumulative probability models within a Bayesian framework were used to estimate differences between the treatment groups. The primary outcome of this health-status analysis was the SAQ summary score (scores range from 0 to 100, with higher scores indicating better health status). All analyses were performed in the overall population and according to baseline angina frequency. RESULTS At baseline, 35% of patients reported having no angina in the previous month. SAQ summary scores increased in both treatment groups, with increases at 3, 12, and 36 months that were 4.1 points (95% credible interval, 3.2 to 5.0), 4.2 points (95% credible interval, 3.3 to 5.1), and 2.9 points (95% credible interval, 2.2 to 3.7) higher with the invasive strategy than with the conservative strategy. Differences were larger among participants who had more frequent angina at baseline (8.5 vs. 0.1 points at 3 months and 5.3 vs. 1.2 points at 36 months among participants with daily or weekly angina as compared with no angina). CONCLUSIONS In the overall trial population with moderate or severe ischemia, which included 35% of participants without angina at baseline, patients randomly assigned to the invasive strategy had greater improvement in angina-related health status than those assigned to the conservative strategy. The modest mean differences favoring the invasive strategy in the overall group reflected minimal differences among asymptomatic patients and larger differences among patients who had had angina at baseline

Initial invasive or conservative strategy for stable coronary disease

BACKGROUND Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain. METHODS We randomly assigned 5179 patients with moderate or severe ischemia to an initial invasive strategy (angiography and revascularization when feasible) and medical therapy or to an initial conservative strategy of medical therapy alone and angiography if medical therapy failed. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. A key secondary outcome was death from cardiovascular causes or myocardial infarction. RESULTS Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-strategy group and 352 occurred in the conservative-strategy group. At 6 months, the cumulative event rate was 5.3% in the invasive-strategy group and 3.4% in the conservative-strategy group (difference, 1.9 percentage points; 95% confidence interval [CI], 0.8 to 3.0); at 5 years, the cumulative event rate was 16.4% and 18.2%, respectively (difference, 121.8 percentage points; 95% CI, 124.7 to 1.0). Results were similar with respect to the key secondary outcome. The incidence of the primary outcome was sensitive to the definition of myocardial infarction; a secondary analysis yielded more procedural myocardial infarctions of uncertain clinical importance. There were 145 deaths in the invasive-strategy group and 144 deaths in the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83 to 1.32). CONCLUSIONS Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years. The trial findings were sensitive to the definition of myocardial infarction that was used